Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis BRITISH JOURNAL OF HAEMATOLOGY Baecklund, E., Natkunam, Y., Backlin, C., Iliadou, A., Askling, J., Ekbom, A., Feltelius, N., Klareskog, L., Enblad, G., Lossos, I. S., Levy, R., Sundstroem, C., Rosenquist, R. 2008; 141 (1): 69-72

Abstract

Diffuse large B-cell lymphomas (DLBCL) can be subdivided into germinal centre (GC)-like and non-GC-like subtypes by CD10, BCL6 and MUM1/IRF4 status. We previously reported that patients with severe rheumatoid arthritis (RA) are at increased risk of non-GC DLBCL. This study examined a new GC-marker, human germinal-centre-associated lymphoma (HGAL) protein, in RA-DLBCL. Of 111, 38 (34%) DLBCL were HGAL-positive and showed less disseminated disease and a tendency toward improved overall survival compared to HGAL-negative cases. This supports that a majority of RA-DLBCL are of non-GC origin, indicating a specific role for activated peripheral B cells in the pathogenesis of RA-DLBCL.

View details for DOI 10.1111/j.1365-2141.2008.07011.x

View details for Web of Science ID 000253757400008

View details for PubMedID 18324968